Simon Moroney
Chairman bij BIOTALYS NV
Vermogen: 608 965 $ op 29-02-2024
Profiel
Dr. Simon E.
Moroney is a Chairman at Biotalys NV and a Vice Chairman at Novartis AG.
He is on the Board of Directors at Novartis AG.
Dr. Moroney was previously employed as a Chief Executive Officer by MorphoSys AG, a Research Associate by University of Cambridge, an Associate-Chemistry Department by Swiss Federal Institute of Technology, an Associate by Harvard Medical School, a President by Government of Germany, a Member-Supervisory Board by ProtAffin Biotechnologie AG, and an Assistant Professor by University of British Columbia.
He received his graduate degree from Waikato University and a doctorate degree from the University of Oxford.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
NOVARTIS AG
0.00% | 31-12-2023 | 5 992 ( 0.00% ) | 608 965 $ | 29-02-2024 |
Actieve functies van Simon Moroney
Bedrijven | Functie | Begin |
---|---|---|
NOVARTIS AG | Director/Board Member | 28-02-2020 |
BIOTALYS NV | Chairman | 01-04-2021 |
Eerdere bekende functies van Simon Moroney
Bedrijven | Functie | Einde |
---|---|---|
MORPHOSYS AG | Chief Executive Officer | 01-09-2019 |
ProtAffin Biotechnologie AG
ProtAffin Biotechnologie AG Pharmaceuticals: MajorHealth Technology ProtAffin was spun out of the Karl-Franzens University of Graz in July 2005. The company currently employs 16 people in modern office and laboratory facilities in Graz and Vienna and plans to expand to 27 by the end of 2009. They are well financed by a syndicate of 5 international venture capital investors. The company has a balanced 'platform-product' strategy: a lead compound in pre-clinical development and a core discovery technology by which they are supporting a sustainable pipeline of products via its unique CellJammer® discovery technology platform. ProtAffin is leveraging its leading technical expertise in protein-glycan interactions to develop novel biological products. They are currently collaborating with a number of university groups in Austria, Germany, Brazil and the UK. They plan to collaborate with Pharma and Biotech companies interested to access its technology for the development of novel anti-inflammatory products with a unique mechanism of action. | Director/Board Member | 17-02-2014 |
University of Cambridge | Corporate Officer/Principal | 01-01-1992 |
Swiss Federal Institute of Technology | Corporate Officer/Principal | 01-01-1989 |
Harvard Medical School | Corporate Officer/Principal | 01-01-1986 |
Opleiding van Simon Moroney
University of Oxford | Doctorate Degree |
Waikato University | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 3 |
---|---|
NOVARTIS AG | Health Technology |
MORPHOSYS AG | Health Technology |
BIOTALYS NV | Process Industries |
Bedrijven in privébezit | 2 |
---|---|
Government of Germany | Government |
ProtAffin Biotechnologie AG
ProtAffin Biotechnologie AG Pharmaceuticals: MajorHealth Technology ProtAffin was spun out of the Karl-Franzens University of Graz in July 2005. The company currently employs 16 people in modern office and laboratory facilities in Graz and Vienna and plans to expand to 27 by the end of 2009. They are well financed by a syndicate of 5 international venture capital investors. The company has a balanced 'platform-product' strategy: a lead compound in pre-clinical development and a core discovery technology by which they are supporting a sustainable pipeline of products via its unique CellJammer® discovery technology platform. ProtAffin is leveraging its leading technical expertise in protein-glycan interactions to develop novel biological products. They are currently collaborating with a number of university groups in Austria, Germany, Brazil and the UK. They plan to collaborate with Pharma and Biotech companies interested to access its technology for the development of novel anti-inflammatory products with a unique mechanism of action. | Health Technology |